An international patient travelled to Zurich for closure of an atrial septal defect (ASD) using a fully bioresorbable occluder.
The procedure was performed by Dr. Horst Sievert together with Dr. Salzberg at Swiss Ablation in close collaboration within the CardioVascular Global (CVG) network.
This case represents very early international experience with this technology outside China and, to our knowledge, the first use of a fully bioresorbable occluder for ASD in Europe.
The intervention was guided by transoesophageal echocardiography.
Unlike conventional devices, bioresorbable occluders are designed to gradually dissolve over time.
This approach may allow closure of the defect without leaving a permanent implant and may help preserve future access to the left atrium if needed.
For selected patients, access to specific expertise and innovative technologies can be an important factor. This is one of the reasons why patients may travel internationally for treatment.
We are currently building further experience and will continue to evaluate long-term outcomes.
Request an international consultation:
https://www.cardiovascular.global/request-a-consultation/
Atrial septal defect visualized by echocardiography
Fully bioresorbable occluder design
Procedure performed at Swiss Ablation, Zurich
Interventional setup during the procedure